Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Sep 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned End Date changed from 1 Dec 2020 to 1 May 2027.
- 07 Feb 2019 Planned primary completion date changed from 1 Dec 2019 to 1 May 2027.